文献速递间质性肺疾病慢阻肺

血管紧张素转换酶抑制剂使用与特发性肺纤维化患者死亡结局的关联

Mortality Outcomes and Angiotensin-Converting Enzyme Inhibitor Use in Patients With Idiopathic Pulmonary Fibrosis.
PubMed 文献 · Chest · 2025-08-14

基于英国临床实践研究数据链等电子健康记录,回顾性分析3579例IPF患者及匹配的COPD对照,按诊断前5年内≥3次ACEI处方定义用药。

要点

  • IPF患者中ACEI使用与全因死亡风险降低独立相关(HR 0.82)。
  • COPD患者中ACEI使用与全因死亡无显著关联(HR 1.09)。
  • 需前瞻性试验证实IPF人群中的上述关联。

核心结论

  • ACEI治疗与IPF患者全因死亡率降低独立相关,但在COPD患者中未发现类似关联。

研究设计与样本

  • 回顾性分析使用临床实践研究数据链GP在线数据库(2019),链接医院统计入院患者护理和死亡登记数据。
  • 纳入3579例IPF患者及匹配的COPD对照,平均年龄74岁,女性36%。
  • ACEI使用定义为诊断前5年内≥3次处方,采用倾向评分匹配年龄、性别和吸烟史。
  • 多变量Cox回归调整年龄、性别、BMI、吸烟状态、多重剥夺指数、糖尿病、慢性肾脏病和常见心血管合并症。
  • IPF队列中使用竞争风险分析处理病因特异性死亡。

主要发现

  • IPF队列中1328例(37%)为ACEI使用者,COPD患者中1061例(30%)为ACEI使用者。

临床怎么用

  • 在IPF患者中,ACEI使用可能与小降低全因死亡风险相关,但需前瞻性试验证实。
  • COPD患者使用ACEI未显示生存获益,临床决策应基于其他适应证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Angiotensin-converting enzyme (ACE) inhibitors are widely used antihypertensive agents with proven cardioprotective effects. Previous mechanistic and clinical studies have suggested that ACE inhibitor therapy may slow disease progression and reduce mortality in idiopathic pulmonary fibrosis (IPF). RESEARCH QUESTION: Does ACE inhibitor use associate with reduced all-cause mortality in a real-world population of patients with IPF, and if so, is the association also present in patients with COPD? STUDY DESIGN AND METHODS: A retrospective analysis was conducted by using electronic health records from the Clinical Practice Research Datalink GP Online Database (2019), linked with Hospital Episode Statistics Admitted Patient Care and Office for National Statistics death registration data. Patients with IPF and COPD were stratified based on ACE inhibitor use (defined as ≥ 3 prescriptions within the 5 years preceding diagnosis) and matched by age, sex, and smoking history using propensity score matching. Multivariable Cox regression analyses were performed, adjusting for age, sex, BMI, smoking status, indices of multiple deprivation, diabetes mellitus, chronic kidney disease, and common cardiovascular comorbidities. In the IPF cohort, competing risk analysis was used to account for cause-specific mortality. RESULTS: The study included 3,579 patients with IPF and matched COPD control participants (mean age, 74 years; 36% female). Among the IPF cohort, 1,328 (37%) were ACE inhibitor users, compared with 1,061 (30%) among patients with COPD. ACE inhibitor use was associated with improved survival, independent of coexisting comorbidities, in patients with IPF (hazard ratio, 0.82; 95% CI, 0.75-0.91; P ≤ .001), but a similar association was not found in patients with COPD (hazard ratio, 1.09; 95% CI, 0.96-1.23; P = .180). INTERPRETATION: In this study, ACE inhibitor therapy was independently associated with reduced all-cause mortality in IPF but not in COPD. Prospective trials are warranted to confirm these findings in IPF populations.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Ozaltin B, Chapman R, Follet T, et al. Mortality Outcomes and Angiotensin-Converting Enzyme Inhibitor Use in Patients With Idiopathic Pulmonary Fibrosis. Chest. 2025. PMID: 40818772. doi:10.1016/j.chest.2025.07.4077

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。